Third-Party Peptide Testing — Why Independent COAs Matter | Regena

A first-party COA is produced by the manufacturer of the peptide. A second-party COA is produced by the buyer or distributor of the peptide. A third-party COA is produced by a laboratory operationally independent from both — no shared ownership, no commercial incentive to over-report purity, no pressure to release a batch that does not meet the specification.

Janoshik Analytical is the most widely cited third-party laboratory in European research-peptide supply. Anresco, Auriga Research and several university-hosted core facilities also operate at the third-party standard. Supplier-internal laboratories — even when technically competent — are not third-party regardless of the analytical quality of their output.

An independent laboratory has no commercial reason to report a higher purity than the batch contains, to under-report related impurities, or to release a batch that fails specification. A supplier-funded internal laboratory has all three of those incentives, even when its analysts are scrupulous. That difference in incentive structure is the entire reason a third-party COA carries more weight.

The point is not that supplier-internal laboratories are dishonest — most are competent and many are scrupulous. The point is that the buyer cannot tell the difference from the outside, and the incentive structure tilts the room. Independence removes the tilt.

Look at four fields: (1) the laboratory name — is it named, and is it the same company as the supplier? (2) the laboratory address — is it published, and is it a different address from the supplier? (3) the analyst signature — is it a named analyst from the laboratory, not a supplier employee? (4) the report formatting — does it look like every other report from the same independent laboratory across the industry, or has it been re-typeset by the supplier?

A supplier-internal COA dressed as third-party will typically fail on at least two of those four. A genuine third-party COA passes all four cleanly. If you cannot tell from the COA itself, ask the supplier directly — and treat the answer as data.

Regena's release rule is straightforward: a batch without an independent third-party COA does not ship. Janoshik Analytical is the default verifier; an orthogonal independent laboratory is used when batch chemistry calls for a second method or when the receiving institution requires a specific accredited laboratory.

The rule exists because the alternative — accepting supplier-internal COAs to keep supply flowing — exposes the receiving researcher to a tilted incentive structure they cannot inspect. Regena will rather delay a batch than ship without independent verification.

Third-party analytical testing covers identity, purity, related impurities and water content for the analysed sample. It does not cover sterility (a separate test), endotoxin (a separate test), residual solvents (a separate test), genotoxic impurities (a separate test) or biological activity (a separate assay). For research-grade in-vitro use the standard third-party COA is sufficient; for sensitive protocols additional testing should be commissioned through the supplier.

Regena adds sterility, endotoxin and residual-solvent analysis on request through the consultations team. The standard third-party COA is shipped on every batch by default.

One underrated benefit of third-party testing is cross-batch comparability. When every batch of a given compound is verified by the same independent laboratory under the same method, the receiving researcher can compare a current batch's purity, related-impurities profile and water content against the previous batch — and notice drift before it affects an experiment.

Regena maintains the published history of independent COAs on the /coa lab reports page exactly so that institutional buyers can audit cross-batch consistency before committing to a multi-batch programme.

If a supplier refuses to provide an independent third-party COA — or only provides an internal report — treat that as a sourcing flag. There are legitimate reasons a batch might be temporarily without a fresh third-party COA (queue at the laboratory, paperwork lag, recent dispatch), but the refusal pattern should not persist across multiple batches.

Regena's position is that every batch ships with the independent COA bundled, printed and electronic. If a research project cannot move forward without verification, the consultations team will hold dispatch until the report is in hand rather than ship blind.

Independent third-party testing is the credibility baseline for research-peptide supply. It is not a premium feature, it is not a marketing claim — it is the minimum analytical evidence a buyer needs to commit a batch to a protocol with confidence. Suppliers that operate to the third-party standard make that clear in their batch documentation; suppliers that do not, signal their position by what is absent from their COA.

Read the COA, check the four laboratory-identity fields, and treat the answer as data. Regena structures every batch around exactly that workflow.